- Home
- EDN vs PHVS Comparison
EDN vs PHVS Comparison
Compare EDN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- PHVS
- Stock Information
- Founded
- EDN 1992
- PHVS 2015
- Country
- EDN Argentina
- PHVS Switzerland
- Employees
- EDN N/A
- PHVS N/A
- Industry
- EDN Electric Utilities: Central
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- PHVS Health Care
- Exchange
- EDN Nasdaq
- PHVS Nasdaq
- Market Cap
- EDN 1.2B
- PHVS 980.9M
- IPO Year
- EDN 2007
- PHVS 2021
- Fundamental
- Price
- EDN $24.95
- PHVS $23.00
- Analyst Decision
- EDN
- PHVS Buy
- Analyst Count
- EDN 0
- PHVS 6
- Target Price
- EDN N/A
- PHVS $37.17
- AVG Volume (30 Days)
- EDN 90.7K
- PHVS 71.6K
- Earning Date
- EDN 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- EDN N/A
- PHVS N/A
- EPS Growth
- EDN N/A
- PHVS N/A
- EPS
- EDN 0.21
- PHVS N/A
- Revenue
- EDN $2,097,707,542.00
- PHVS N/A
- Revenue This Year
- EDN $51.74
- PHVS N/A
- Revenue Next Year
- EDN N/A
- PHVS N/A
- P/E Ratio
- EDN $6.09
- PHVS N/A
- Revenue Growth
- EDN 37.57
- PHVS N/A
- 52 Week Low
- EDN $13.78
- PHVS $11.51
- 52 Week High
- EDN $51.69
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- EDN 37.00
- PHVS 70.21
- Support Level
- EDN $24.25
- PHVS $21.84
- Resistance Level
- EDN $25.48
- PHVS $24.41
- Average True Range (ATR)
- EDN 1.36
- PHVS 1.74
- MACD
- EDN 0.04
- PHVS 0.54
- Stochastic Oscillator
- EDN 10.40
- PHVS 76.27
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.